Jefferies reiterated a Buy rating and $44 price target on Viridian Therapeutics (VRDN), noting the shares rose after Roche’s (RHHBY) mixed Phase 3 results for its IL-6mAb Satralizumab in thyroid eye diseases, or TED. One pivotal trial didn’t hit the primary endpoint while the other showed efficacy meaningfully weaker than Veridian’s Veligrotug, the analyst tells investors in a research note. The firm added that these results remove key comp pressure and position ‘003 as the leading Q4W+ SubQ therapy for thyroid eye diseases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics Positioned for Success Amid Competitive Challenges in TED Market
- Buy Rating Affirmed for Viridian Therapeutics Amid Promising Developments in Thyroid Eye Disease Treatment
- Viridian Therapeutics’ Veligrotug Outperforms Roche’s Satralizumab in TED Treatment, Supporting Buy Rating
- Viridian Therapeutics: Buy Rating Affirmed on Pivotal Program Completion and Promising Pipeline Outlook
- Promising Developments and Strategic Advancements Justify Buy Rating for Viridian Therapeutics